Search

Royalty Pharma PLC (Class A)

Slēgts

SektorsVeselības aprūpe

63.87 1.27

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

62.45

Max

63.92

Galvenie mērījumi

By Trading Economics

Ienākumi

-589M

-295M

Pārdošana

44M

674M

P/E

Sektora vidējais

32.665

56.659

EPS

1.32

Dividenžu ienesīgums

1.5

Peļņas marža

-43.713

Darbinieki

100

EBITDA

-387M

176M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+5.38% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

1.50%

2.18%

Nākamie ieņēmumi

2026. g. 4. nov.

Nākamais dividenžu datums

2026. g. 10. sept.

Nākamais Ex dividenžu datums

2026. g. 13. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.6B

35B

Iepriekšējā atvēršanas cena

62.6

Iepriekšējā slēgšanas cena

63.87

Ziņu noskaņojums

By Acuity

81%

19%

315 / 340 Rangs Healthcare

Royalty Pharma PLC (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. sept. 23:06 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

2026. g. 1. sept. 20:09 UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

2026. g. 31. aug. 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

2026. g. 28. aug. 20:07 UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

2026. g. 27. aug. 23:11 UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

2026. g. 26. aug. 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

2026. g. 25. aug. 20:07 UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

2026. g. 24. aug. 20:06 UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

2026. g. 21. aug. 19:26 UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

2026. g. 20. aug. 23:11 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

2026. g. 19. aug. 20:02 UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

2026. g. 18. aug. 23:21 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

2026. g. 17. aug. 19:36 UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

2026. g. 15. aug. 00:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

2026. g. 14. aug. 19:46 UTC

Event
Social Media

Royalty Pharma PLC declared a $0.235 per share dividend today, with shares advancing since Thursday's close and near the upper end of their one-month range.

2026. g. 13. aug. 20:02 UTC

Social Media

Royalty Pharma PLC shares are lower amid a $100 million royalty agreement with Zealand Pharma for rusfertide rights, reflecting unusual trading activity.

2026. g. 12. aug. 20:01 UTC

Royalty Pharma PLC shares are higher today, supported by a broader market trend of gains since Tuesday. The stock is seeing unusually high trading volume.

2026. g. 11. aug. 19:56 UTC

Royalty Pharma PLC shares are trading higher, reaching a session high earlier today. No specific news was identified to explain the price movement.

2026. g. 10. aug. 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting notable strength and unusual activity since Monday's close, with no specific news identified.

2026. g. 7. aug. 23:41 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting notable gains since Friday's close amid a shift toward a dovish monetary policy outlook.

2026. g. 6. aug. 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

2026. g. 5. aug. 19:31 UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

2026. g. 4. aug. 19:26 UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

2026. g. 3. aug. 23:46 UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

2026. g. 1. aug. 00:03 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

2026. g. 31. jūl. 23:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

2026. g. 30. jūl. 22:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

2026. g. 29. jūl. 19:27 UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

2026. g. 28. jūl. 23:46 UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

2026. g. 27. jūl. 16:46 UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

Salīdzinājums

Cenas izmaiņa

Royalty Pharma PLC (Class A) Prognoze

Cenas mērķis

By TipRanks

5.38% augšup

Prognoze 12 mēnešiem

Vidējais 65.67 USD  5.38%

Augstākais 70 USD

Zemākais 62 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Royalty Pharma PLC (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

7

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

315 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat